Finance

Hansa Biopharma's €115M Deal Expands Kidney Treatment

By Daybreak Brief Editorial Team

Hansa Biopharma has struck a €115 million deal with SERB Pharmaceuticals to license IDEFIRIX, a groundbreaking kidney transplant treatment, across Europe and the MENA region. This agreement boosts Hansa's financial strength for a strong US launch and a path to profitability, pending US approval in 2026. What does it mean for you? If you're in Europe or MENA and in need of a kidney transplant, this could mean better access to life-changing treatment options, thanks to Hansa and SERB teaming up.

Original source Read the full story →
▲ 828 voters this week
How we select stories →
More from this briefing
Huawei Unveils Future-Ready AI Data Centers Strategy → Aitech Secures $63M Deal for Indian Helicopter Tech → Huawei Unveils AI-Powered Eco-Friendly Data Centers → Saudi Arabia Debuts First Quantum Computing Platform → Entolimod: Revolutionizing Radiation Syndrome Treatment → KuCoin EU Champions Responsible Crypto Growth in Europe → US-China Summit: "Strategic Stability" Sparks Debate → EDB Boosts Uzbekistan's FinTech with $70M Investment → Mobility Global Gears Up for Independence Shift → Huawei Unveils Game-Changing AI Data Centers → Aitech Lands $63M Deal for Indian Helicopter Tech → Allspring Funds Boost Payouts, Caution Advised → Sip Your Way to Better Heart Health → TERREPOWER's Green Revolution: Big CO2 Reductions → Huawei Powers AI Future with Smart Data Centers → S&P Global Boosts Dividend for 50th Year → Revolutionizing Drug Discovery with XPressMAX Kit →

Get stories like this every morning.

Five-minute intelligence briefing — in your inbox at 6 AM.

Subscribe now →